A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome

摘要: Accumulating evidence supports the view that an imbalance of gut bacteria contributes to IBS, and increasing mass beneficial species may reduce numbers pathogenic help alleviate symptoms. In this double-blind trial 400 adult patients with moderate-to-severe symptomatic diarrhea-predominant IBS (IBS-D) were randomized treatment multi-strain probiotic Bio-Kult® (14 different bacterial strains) or placebo for 16 weeks. The change in severity frequency abdominal pain was primary outcome measure. Probiotic significantly improved IBS-D. A 69% reduction versus 47% (p < 0.001) equates a 145 point on IBS-severity scoring system (IBS-SSS). proportion who rated their symptoms as reduced from 100% at baseline 14% follow-up (month 5) 48% (p < 0.001). Also, number bowel motions per day month 2 onwards group compared (p < 0.05). addition relieving symptoms, markedly all dimensions quality life 34-item IBS-Quality Life (IBS-QoL) questionnaire. No serious adverse events reported. associated significant improvement IBS-D well-tolerated. These results suggest probiotics confer benefit which deserves further investigation. [Clinicaltrials.gov NCT03251625 ; retrospectively registered August 9, 2017].